TrialCancer medicine2019

Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients.

Tommy A Brown et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.